The FDA has approved Viberzi (eluxadoline) and Xifaxan (rifaximin) to treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women, the agency announced Wednesday.
IBS affects 10% to 15% of adults in the U.S.; the IBS-D subtype is characterized by having loose or watery stools at least 25% of the time.
"For some people, IBS can be quite disabling, and no one medication works for all patients suffering from this gastrointestinal disorder," Julie Beitz, MD, director of FDA's Office of Drug Evaluation III, said in a press release.
"The approval of two new therapies underscores the FDA's commitment to providing additional treatment options for IBS patients and their doctors."
Không có nhận xét nào:
Đăng nhận xét